强直性肌营养不良1型(DM1) 1例报告
A Case Report of Type 1 Myotonic Dystrophy (DM1)
摘要: 强直性肌营养不良(myotonic dystrophy, DM)是一种罕见的多系统受累的常染色体显性遗传疾病,由DNA串联重复序列扩增导致RNA功能突变所致,各年龄阶段均可发病。由于该病个体临床表现差异较大且轻重程度不一,给诊断带来一定的困难。对于考虑DM的患者应详细询问病史、家族史,并结合影像学、肌电图、肌肉活检提高对本病的诊断,最终通过基因检测确诊。DM病程进展缓慢,轻者多数不影响寿命,重型患者早期可出现心源性猝死,后期可有肺部感染、营养障碍等致死性并发症。遗憾的是目前DM无特效治疗方法,主要是对症治疗以及对并发症的防治。本文对1例成人型DM1型病例进行报告,旨在提高对该病的认识与诊断水平。
Abstract: Myotonic dystrophy (DM) is a rare, multisystemic, autosomal dominant genetic disorder characterized by the expansion of DNA tandem repeat sequences, resulting in RNA functional mutations that can impact individuals across all age groups. Given the broad spectrum of clinical manifestations and variable severity, diagnosing DM poses significant challenges. In patients with suspected DM, it is imperative to conduct a thorough medical and family history review, complemented by imaging studies, electromyography, and muscle biopsies to enhance diagnostic accuracy. Definitive diagnosis, however, relies on genetic testing. The progression of the disease is typically slow; mild cases often do not compromise life expectancy. Conversely, severe cases may lead to early cardiac sudden death and, in later stages, potentially fatal complications such as pulmonary infections and nutritional deficiencies. Regrettably, there are currently no curative treatments available for DM, and therapeutic strategies primarily focus on alleviating symptoms and managing complications. This case report aims to highlight an instance of adult-onset DM1, underscoring the importance of heightened awareness and improved diagnostic approaches for this condition.
文章引用:田亚萍, 宫建, 叶德彩, 王广英. 强直性肌营养不良1型(DM1) 1例报告[J]. 临床医学进展, 2025, 15(1): 2167-2174. https://doi.org/10.12677/acm.2025.151285

参考文献

[1] Wenninger, S., Montagnese, F. and Schoser, B. (2018) Core Clinical Phenotypes in Myotonic Dystrophies. Frontiers in Neurology, 9, Article 303. [Google Scholar] [CrossRef] [PubMed]
[2] 刘春苗, 张静, 于湄, 等. 强直性肌营养不良临床表现,基因检测和骨骼肌活检特点分析[J]. 中国神经精神疾病杂志, 2023, 49(5): 274-279.
[3] Bielen, J., Schepers, S., Termote, B., Vanwyck, R. and Souverijns, G. (2016) Imaging in Myotonic Dystrophy Type 1—Case Reports. Journal of the Belgian Society of Radiology, 100, Article 81. [Google Scholar] [CrossRef] [PubMed]
[4] LoRusso, S., Weiner, B. and Arnold, W.D. (2018) Myotonic Dystrophies: Targeting Therapies for Multisystem Disease. Neurotherapeutics, 15, 872-884. [Google Scholar] [CrossRef] [PubMed]
[5] Yu, H., Laberge, L., Jaussent, I., Bayard, S., Scholtz, S., Morales, R., et al. (2011) Daytime Sleepiness and REM Sleep Characteristics in Myotonic Dystrophy: A Case-Control Study. Sleep, 34, 165-170. [Google Scholar] [CrossRef] [PubMed]
[6] Gadalla, S.M., Pfeiffer, R.M., Kristinsson, S.Y., Björkholm, M., Landgren, O. and Greene, M.H. (2015) Brain Tumors in Patients with Myotonic Dystrophy: A Population‐Based Study. European Journal of Neurology, 23, 542-547. [Google Scholar] [CrossRef] [PubMed]
[7] De Serres-Bérard, T., Pierre, M., Chahine, M. and Puymirat, J. (2021) Deciphering the Mechanisms Underlying Brain Alterations and Cognitive Impairment in Congenital Myotonic Dystrophy. Neurobiology of Disease, 160, Article 105532. [Google Scholar] [CrossRef] [PubMed]
[8] Mahadevan, M.S., Yadava, R.S. and Mandal, M. (2021) Cardiac Pathology in Myotonic Dystrophy Type 1. International Journal of Molecular Sciences, 22, Article 11874. [Google Scholar] [CrossRef] [PubMed]
[9] Boussaïd, G., Wahbi, K., Laforet, P., Eymard, B., Stojkovic, T., Behin, A., et al. (2018) Genotype and Other Determinants of Respiratory Function in Myotonic Dystrophy Type 1. Neuromuscular Disorders, 28, 222-228. [Google Scholar] [CrossRef] [PubMed]
[10] Jia, Y., Dong, C., Xue, J., Duan, X., Xu, M., Su, X., et al. (2022) Myotonic Dystrophy Type 1 Presenting with Dyspnea: A Case Report. World Journal of Clinical Cases, 10, 7060-7067. [Google Scholar] [CrossRef] [PubMed]
[11] Nugent, A., Smith, I.E. and Shneerson, J.M. (2002) Domiciliary-Assisted Ventilation in Patients with Myotonic Dystrophy. Chest, 121, 459-464. [Google Scholar] [CrossRef] [PubMed]
[12] Kim, C., Park, J., Park, D., Kim, D. and Park, J. (2021) Opioid Use May Be Associated with Postoperative Complications in Myotonic Dystrophy Type 1 with High-Grade Muscular Impairment. Scientific Reports, 11, Article No. 8. [Google Scholar] [CrossRef] [PubMed]
[13] 阎雪晶, 欧阳嶷, 何志义, 等. 强直性肌营养不良1型患者的眼部症状分析[J]. 中国医科大学学报, 2016, 45(2): 97-100.
[14] Winters, S.J. (2021) Endocrine Dysfunction in Patients with Myotonic Dystrophy. The Journal of Clinical Endocrinology & Metabolism, 106, 2819-2827. [Google Scholar] [CrossRef] [PubMed]
[15] Win, A.K., Perattur, P.G., Pulido, J.S., Pulido, C.M. and Lindor, N.M. (2012) Increased Cancer Risks in Myotonic Dystrophy. Mayo Clinic Proceedings, 87, 130-135. [Google Scholar] [CrossRef] [PubMed]
[16] Mohamed, S., Pruna, L. and Kaminsky, P. (2013) Augmentation du risque de tumeurs dans la dystrophie myotonique de type 1. La Presse Médicale, 42, e281-e284. [Google Scholar] [CrossRef] [PubMed]
[17] 卜碧涛, 李悦. 强直性肌营养不良[J] .中华神经科杂志, 2019, 52(8): 654-658.
[18] Thornton, C.A. (2014) Myotonic Dystrophy. Neurologic Clinics, 32, 705-719. [Google Scholar] [CrossRef] [PubMed]
[19] Thornton, C.A., Moxley, R.T., Eichinger, K., Heatwole, C., Mignon, L., Arnold, W.D., et al. (2023) Antisense Oligonucleotide Targeting DMPK in Patients with Myotonic Dystrophy Type 1: A Multicentre, Randomised, Dose-Escalation, Placebo-Controlled, Phase 1/2a Trial. The Lancet Neurology, 22, 218-228. [Google Scholar] [CrossRef] [PubMed]